William David Henner
Oregon Health & Science University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by William David Henner.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2000
Jeffrey E. McWilliams; Adam J. Evans; Tomasz M. Beer; Peter E. Andersen; James I. Cohen; Edwin C. Everts; William David Henner
To assess whether genetic polymorphisms implicated as risk factors for other tobacco‐associated malignancies are associated with altered risk of head and neck squamous cell carcinoma.
British Journal of Cancer | 2004
T M Beer; M Garzotto; William David Henner; Kristine M. Eilers; Emily M. Wersinger
Recently, completed phase III studies demonstrated a survival benefit for a fixed number of cycles of docetaxel-containing chemotherapy treatment of androgen-independent prostate cancer (AIPC). Management of patients who respond well to initial chemotherapy for AIPC remains ill-defined. We previously reported that in a select group of such patients, retreatment with the same regimen was feasible and was associated with quality of life gains. Here, we report that multiple cycles of such intermittent chemotherapy are feasible. We prospectively tested intermittent chemotherapy in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml−1 (22% of the 37 patients who were initially treated with this regimen). Chemotherapy was suspended until a rise in PSA ⩾50% and 1 ng ml−1. The median duration of the first treatment holiday was 20 weeks (13–74 weeks) and all patients retained sensitivity to retreatment. Four patients were eligible for a second chemotherapy holiday, and the median duration was 21 weeks (17–28 weeks). Two patients elected to take a third chemotherapy holiday, which lasted 10 and 28 weeks. The median time to treatment failure was 26.5 months (95% CI 23.6–29.4 months), and the median survival is 41 months (95% CI 33.7–48.3 months). Multiple cycles of intermittent chemotherapy interrupted by clinically meaningful treatment holidays are feasible in a subset of AIPC patients treated with this docetaxel-containing regimen. Intermittent chemotherapy for AIPC is feasible and deserves further study.
British Journal of Cancer | 2003
T M Beer; M Garzotto; William David Henner; Kristine M. Eilers; Emily M. Wersinger
Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml−1. Chemotherapy was suspended until a rise in PSA⩾50% and 1 ng ml−1. The median duration of treatment holiday was 20 weeks (13–43+weeks) and all patients retained sensitivity to re-treatment. Chemotherapy holiday was associated with an improvement of fatigue (P=0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.
Prostate Cancer and Prostatic Diseases | 2002
Tomasz M. Beer; Adam J. Evans; K M Hough; Bruce A. Lowe; Jeffrey E. McWilliams; William David Henner
Glutathione S-transferase P1 (GSTP1) is markedly downregulated in prostate cancer and prostatic intraepithelial neoplasia compared to normal prostate tissue. Downregulation of GSTP1 may, therefore, be an early event in prostate carcinogenesis. An A→G polymorphism at nucleotide 313 results in an amino acid substitution (Ile105Val) in the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1. In a study of 36 prostate cancer patients, Harries et al. reported that the Ile/Ile genotype is associated with a decreased risk of prostate cancer (odds ratio 0.4 (0.17–0.82)). We sought to confirm this finding and to examine the impact of this polymorphism together with several related polymorphisms implicated as risk factors for carcinogen-associated malignancies. One hundred and seventeen patients with prostate adenocarcinoma and 183 population-based controls were recruited to this case–control study. Genotyping of the GSTP1 (Ile105Val), GSTM1 (null), GSTT1 (null) and CYP1A1 (Ile462Val) genes was performed using polymerase chain reaction (PCR) based techniques on DNA prepared from peripheral blood. A questionnaire was used to collect demographic information from each subject. Cases were significantly older (P<0.0001) and had significantly greater family history of prostate cancer (P<0.0001), confirming known risk factors for this disease. By χ2 analysis, none of the genotype distributions varied among cases and controls. Using a logistic regression model to control for known risk factors we were also unable to demonstrate a significant association with prostate cancer for any of the polymorphisms tested. This population fails to identify a relationship between the above polymorphisms and prostate adenocarcinoma.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2004
Adam J. Evans; William David Henner; Kristi Eilers; Michelle A. Montalto; Emily M. Wersinger; Peter E. Andersen; James I. Cohen; Edwin C. Everts; Jeffrey E. McWilliams; Tomasz M. Beer
Background. Glutathione S‐transferase T1 detoxifies some environmental carcinogens while activating others and is deleted in 15% to 38% of humans. We sought to determine whether GSTT1 genotype and genotypes of several related genes are associated with risk of squamous cell carcinoma of the head and neck (HNSCC).
The New England Journal of Medicine | 2000
Bandana Walkhom; F.T. Fraunfelder; William David Henner
To the Editor: Capecitabine (Xeloda, Roche Laboratories) is an orally administered fluoropyrimidine carbamate used for the treatment of metastatic breast cancer and colon cancer.1–4 We describe two...
Urologic Oncology-seminars and Original Investigations | 2003
Tomasz M. Beer; Kristine M. Eilers; Mark Garzotto; M.J Egorin; Bruce A. Lowe; William David Henner; J.T Hsieh
PURPOSE To determine the safety and efficacy of weekly high-dose oral calcitriol (Rocaltrol, Roche Pharmaceuticals, Basel, Switzerland) and docetaxel (Taxotere, Aventis Pharmaceuticals, Bridgewater, NJ) in patients with metastatic androgen-independent prostate cancer (AIPC). PATIENTS AND METHODS Thirty-seven patients were treated with oral calcitriol (0.5 micro g/kg) on day 1 followed by docetaxel (36 mg/m(2)) on day 2, repeated weekly for 6 weeks of an 8-week cycle. Patients maintained a reduced calcium diet and increased oral hydration. Prostate-specific antigen (PSA) response was the primary end point, which was defined as a 50% reduction in PSA level confirmed 4 weeks later. RESULTS Thirty of 37 patients (81%; 95% confidence interval [CI], 68% to 94%) achieved a PSA response. Twenty-two patients (59%; 95% CI, 43% to 75%) had a confirmed > 75% reduction in PSA. Eight of the 15 patients with measurable disease (53%; 95% CI, 27% to 79%) had a confirmed partial response. Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable). Overall survival at 1 year was 89% (95% CI, 74% to 95%). Treatment-related toxicity was generally similar to that expected with single-agent docetaxel. Pharmacokinetics of either calcitriol or docetaxel were not affected by the presence of its companion drug in an exploratory substudy. CONCLUSION The combination of weekly oral high-dose calcitriol and weekly docetaxel is a well-tolerated regimen for AIPC. PSA and measurable disease response rates as well as time to progression and survival are promising when compared with contemporary phase II studies of single-agent docetaxel in AIPC. Further study of this regimen is warranted.
Archive | 1999
William David Henner; Tomasz M. Beer
Archive | 2001
Gail M. Clinton; Adam J. Evans; William David Henner
Archive | 2007
John G. Curd; John F.W. Keana; Alshad S. Lalani; Paul B. Westberg; Bradford S. Goodwin; William David Henner